IN BRIEF: SkinBioTherapeutics raises PS4 million for Superdrug deal

Related news

SkinBioTherapeutics PLC - Newcastle Upon Tyne, England-based life science firm focused on skin health - Raises £4.2 million from the sale of 24.7 million new shares at 17 pence each. This is split between 24.1 million shares sold via placing and subscription, and 587,191 sold in an offer to retail investors. SkinBioTherapeutics announced the equity raise on Monday, saying it is to support an exclusive commercial agreement with Superdrug Stores PLC to roll-out AxisBiotix food supplements across the UK. The supplements are meant to alleviate inflammatory skin conditions.

Current stock price: 16.75p for £39.2 million market capitalisation

12-month change: up 72%

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Contract wins

Ways to help you invest your money

Our investment accounts

Put your money to work with our range of investment accounts. Choose from ISAs, pensions, and more.

Need some investment ideas?

Let us give you a hand choosing investments. From managed funds to favourite picks, we’re here to help.

Read our expert tips and insights

Our investment experts share their knowledge on how to keep your money working hard across the markets.